UBE1L upregulation in APL upon RA treatment leads to the degradation of oncogenic fusion protein promyelocytic leukemia (PML)-RA receptor α (RARα) (PML-RARα), resulting in the prevention of APL40. The gene discussed is PML; the disease is acute promyelocytic leukemia.